Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Regul Toxicol Pharmacol 32(1):5667 Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA (2011) Managing the challenge of chemically reactive metabolites in drug development
Matt Williams: Anytime
As shortages resolve, regulators are less willing to tolerate parallel supply channels for approved drugs
We want to eliminate as much risk as possible during the treatment process
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
US$ 22.65
US$ 28.05
US$ 24.64
